Evidence map›Paper›PMID 37476485›Full record

ArticleBehavioural neurology2023

Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters.

Mahdieh Anoush, Soroush Bijani, Fatemeh Moslemifar, Fatemeh Jahanpour, Ali Kalantari-Hesari, Mir-Jamal Hosseini

Open access · goldAbstract read
In one paragraph

Article in Behavioural neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mahdieh AnoushZanjan Applied Pharmacology Research Center, Zanjan University of Medical sciences, Zanjan, Iran.ORCID https://orcid.org/0000-0002-5341-5862
Soroush BijaniZanjan Applied Pharmacology Research Center, Zanjan University of Medical sciences, Zanjan, Iran.ORCID https://orcid.org/0000-0003-2501-3978
Fatemeh MoslemifarZanjan Applied Pharmacology Research Center, Zanjan University of Medical sciences, Zanjan, Iran.
Fatemeh JahanpourZanjan Applied Pharmacology Research Center, Zanjan University of Medical sciences, Zanjan, Iran.
Ali Kalantari-HesariDepartment of Pathobiology, Faculty of Veterinary Science, Bu-Ali Sina University, Hamedan, Iran.ORCID https://orcid.org/0000-0002-9079-753X
Mir-Jamal HosseiniZanjan Applied Pharmacology Research Center, Zanjan University of Medical sciences, Zanjan, Iran.ORCID https://orcid.org/0000-0001-6300-7398
Zanjan University of Medical Sciences · IRBu-Ali Sina University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD), as the main cause of dementia, has a progressive and neurodegenerative pattern with number of cases increasing over the next decades. Therefore, discovering an effective treatment with the ability to invert memory impairment and pathophysiological events of AD seems to be required. The present study performed to investigate the probable effects of Edaravone (EDV) in AD-like disorder induced by intracerebroventricular streptozotocin (ICV-STZ) administration in mice. This study also compares the two different methods of ICV-STZ in the memory impairment induction. NMRI male mice were administrated with 3 mg/kg of STZ for two times during 48 hours span, and after 24 hours, animals were treated with EDV (5 and 10 mg/kg), Donepezil, and Memantine for 14 days. After behavioral tests regarding memory and cognitive function, animals were sacrificed, and the hippocampi were utilized for further analyses. Our results demonstrated that administration of STZ induced memory impairment in the Morris water maze (MWM) test and decreased the discriminative factor in novel object recognition (NOR). The biochemical output shows a significant decrease in ferric reducing antioxidant power (FRAP) and glutathione (GSH) levels followed by increase in malondialdehyde (MDA) and protein carbonylation (PCO) levels. The output showed no difference between the patterns of AD-like disorder induction. Following our treatment groups, administration of EDV (5 and 10 mg/kg), Donepezil, and Memantine significantly improved memory performance and discriminatory behavior. Aforementioned treatments managed to improve FRAP and GSH content of hippocampus, while significantly attenuating MDA, PCO, and nitric oxide overproduction. In addition, no significant difference has been observed between the effect of 5 and 10 mg/kg EDV application. It was supposed that EDV managed to ameliorate memory dysfunction, discriminatory behavior, oxidative stress, and cellular antioxidant power in a dose-independent pattern in mice.

Indexed as

Alzheimer DiseaseAntioxidantsAnimalsDisease Models, AnimalDonepezilEdaravoneInflammationMaleMaze LearningMemantineMemory DisordersMiceOxidative StressRatsRats, WistarStreptozocinAntioxidantsDonepezilEdaravoneMemantineStreptozocin

Identifiers

PMID37476485
PMCPMC10356234
OpenAlexW4384072148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.